Attenuated Salmonella typhimurium Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent
The DOI matches its Crossref record.
Abstract
Currently, there is no long-term effective treatment for unresectable hepatic malignancies. Salmonella sp. are known to naturally track to the liver during active infection. To develop a biological vector for delivery of Interleukin-2 (IL-2) to the liver for anti-tumor purposes, the avirulent and highly immunogenic chi 4550 strain of Salmonella typhimurium was used as a vector for IL-2. The gene for human IL-2 was cloned into plasmid pYA292 (renamed pIL-2) and inserted into the attenuated Salmonella typhimurium and renamed [chi 4550 (pIL-2)]. This transformant was found to produced biologically active IL-2 demonstrated by NK cell activation in a 4 hour chromium release cytotoxicity assay. To determine anti-tumor potential, MCA-38 murine adenocarcinoma cells were injected intrasplenically into C57BL/6 mice to produce hepatic metastases and metastases were subsequently enumerated after 12 days. Statistical significance was determined by ANOVA with Fisher's test for significance. Hepatic metastases enumerated by blinded observers revealed that the mean number of metastases was 106.4 in control mice, 103.7 in mice gavage fed attenuated salmonella without IL-2 [chi 4550(pYA292)], and 44.3 in mice fed the chi 4550(pIL2); (ANOVA: p < 0.01). Culture of livers and spleens in mice administered a single gavage dose of salmonella demonstrated persistent colonization for up to 4 weeks. No observable toxicity was seen to either IL-2 or salmonella. These studies demonstrate that the chi 4550(pIL2) is a novel form of in vivo biotherapy which produces biologically active IL-2 and employs the oral route of administration to stimulate an immune response against malignancy in the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Low, K. B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., Ash, O., Carmichael, E., Chakraborty, A., Fischer, J., et al. (1999) · Nature Biotechnology · doi:10.1038/5205 · Cited by 476
Engineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460
(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Metadata
- Authors
- Saltzman, D. A., Heise, C. P., Hasz, D. E., Zebede, M., Kelly, S. M., Curtiss, R., Leonard, A. S., & Anderson, P. M.
- Venue
- Cancer Biotherapy and Radiopharmaceuticals
- Publisher
- SAGE Publications
- Published
- 1996-04
- Volume
- 11
- Issue
- 2
- Pages
- 145-153
- ISSN
- 1084-9785 (ISSN-L)
- 1557-8852
- OpenAlex
- W1996239683
- Cited by
- 100
- References
- 0
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Attenuated Salmonella typhimurium Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent. https://app.cochat.ai/papers/10.1089/cbr.1996.11.145
- The paper
- Saltzman, D. A., Heise, C. P., Hasz, D. E., Zebede, M., Kelly, S. M., Curtiss, R., Leonard, A. S., & Anderson, P. M. (1996). Attenuated Salmonella typhimurium Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor Agent. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.1996.11.145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.